Policies and incentives for developing Oman’s pharma industry
Published: 04:10 PM,Oct 10,2026 | EDITED : 08:10 PM,Oct 10,2026
The development of a competitive pharmaceutical and medical devices industry in Oman requires more than attracting individual investments. It requires a targeted industrial policy and incentive framework capable of attracting anchor investors, developing domestic capabilities, connecting local companies to global value chains and encouraging firms to move progressively towards higher-value activities.
International experience shows that successful pharmaceutical and medical-device clusters have generally been supported by a combination of investment incentives, investor facilitation, local supplier development, human-capital policies, research and development support, and specialised infrastructure.
One of the most important policy lessons is that investment incentives should be targeted rather than generic.
Ireland, Costa Rica and Singapore used proactive investment-promotion strategies to identify priority companies and industries, develop tailored investment packages and actively support investors after establishment. For Oman, this approach could be applied to pharmaceutical manufacturers, medical-device producers, biotechnology companies, contract manufacturers and companies with regional export potential.
The incentive package should therefore be linked to measurable economic outcomes. Instead of providing incentives simply for establishing a factory, Oman could consider linking incentives to indicators such as investment value, number and quality of jobs created, exports, local procurement, technology transfer, training of Omani workers and research and development activities.
This would transform incentives from a cost to the government into a policy instrument for achieving specific industrial-development objectives.
A second important policy is investment aftercare. International experience demonstrates that attracting an investor is only the beginning. A dedicated industry-focused team should maintain regular engagement with existing investors, identify barriers to expansion and facilitate reinvestment. Companies that successfully establish operations in Oman should be encouraged to expand production, introduce new products, develop regional export platforms and establish research or technical centres.
The third policy area is the development of local supplier linkages. Foreign pharmaceutical and medical-device companies should be encouraged to source an increasing share of eligible goods and services from competitive Omani companies. This could be supported through supplier-development programmes, technical assistance, quality certification, financing and matchmaking between multinational companies and local SMEs.
The objective should not be to impose local-content requirements without regard to competitiveness. Instead, Oman could adopt a capability-based local-content approach, where incentives are provided to multinational companies that actively develop qualified Omani suppliers and transfer knowledge and technology.
A fourth policy area is the development of specialised human capital.
Pharmaceutical manufacturing requires highly specialised capabilities in production, quality assurance, laboratory testing, regulatory affairs, engineering and research. Government support could therefore include targeted training programmes designed jointly with investors, universities and technical institutions. Companies receiving major investment incentives could be encouraged to establish structured training and skills-transfer programmes for Omani employees.
Research and development should form another component of the incentive framework. Singapore provides an important example of how public policy can gradually move an industry from manufacturing towards higher-value research and innovation activities. Oman could introduce additional incentives for companies that establish R&D centres, clinical research capabilities, testing laboratories, product-development facilities or regional technical centres.
Such incentives could be differentiated according to the level of value added. A manufacturing investment could receive a basic package, while companies undertaking R&D, exporting from Oman, developing local suppliers or employing highly skilled Omanis could qualify for enhanced incentives.
Infrastructure policy is equally important. The development of pharmaceutical clusters in locations such as Salalah and Khazaen should be supported by specialised facilities including testing laboratories, quality-control infrastructure, cold-chain logistics, waste-management systems and training facilities. However, international experience suggests that infrastructure should be developed in line with actual industrial demand rather than simply constructing facilities in anticipation of investors.
Another important policy instrument is government procurement. Where appropriate and consistent with quality, safety and value-for-money requirements, public procurement can help create an initial market for locally manufactured pharmaceutical and medical products. This can provide domestic producers with the scale and market experience needed to become internationally competitive.
The policy framework should therefore move from a single incentive model towards a tiered incentive system. The first tier could support strategic investment and establishment; the second could reward employment, local sourcing and exports; and the third could provide enhanced support for R&D, technology transfer and regional headquarters or centres of excellence.
The experience of Costa Rica demonstrates the potential impact of this approach. Its medical-device industry developed from virtually no exports in the late 1990s into a major export industry. Ireland similarly used targeted investment attraction, skills development and strong links with multinational companies to build a globally competitive medical-device sector. Singapore went further by combining investment attraction with research, human capital and institutional coordination.
For Oman, the key lesson is that incentives should not be viewed simply as tax reductions or financial concessions. The most effective incentive system is one that changes investor behaviour and encourages activities that generate wider economic benefits.
The future pharmaceutical cluster should therefore be supported by a policy package built around six objectives: Attract strategic investors encourage reinvestment develop Omani suppliers create skilled employment increase exports promote R&D and technology transfer.
Such a framework would allow Oman to use its domestic market, economic zones, logistics advantages and emerging industrial capabilities as a platform for building a competitive pharmaceutical and medical-device industry.
The ultimate objective should be to move from import substitution to competitive manufacturing and then to regional and global value chains. In this model, incentives become a strategic tool for industrial transformation, supporting not only pharmaceutical production but also the wider objectives of Oman’s Manufacturing Strategy 2040: diversification, productivity, employment, technology transfer and sustainable non-oil exports.